Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Piramal PharmaNSE:PPLPHARMA -1.84%50 Dividend Yield % is 0.07% as of Aug. 13, 2026, which is 17% above its 10-year median of 0.06. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 50/100 and a GF Value™ of ₹190.03 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 511 Drug Manufacturers companies, Piramal Pharma ranks worse than 98.43% on this metric.
As of today (2026-08-13), the Trailing Annual Dividend Yield of Piramal Pharma is 0.07%.
The historical rank and industry rank for Piramal Pharma's Dividend Yield % or its related term are showing as below:
NSE:PPLPHARMA'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.04 Med: 0.06 Max: 0.1
Current: 0.07
During the past 6 years, the highest Dividend Yield of Piramal Pharma was 0.10%. The lowest was 0.04%. And the median was 0.06%.
NSE:PPLPHARMA's Dividend Yield % is ranked worse than 98.43% of 511
companies
in the Drug Manufacturers industry
Industry Median: 1.94
vs NSE:PPLPHARMA: 0.07
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Piramal Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Piramal Pharma Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Piramal Pharma's Dividend Yield % falls into.
Piramal Pharma (NSE:PPLPHARMA) has a Dividend Yield % of 0.07% as of Aug. 13, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Piramal Pharma and its competitors. This is 17% above median its historical median of 0.06. Over the past decade, Piramal Pharma's Dividend Yield % has ranged from 0.04 to 0.10. According to the industry distribution chart, Piramal Pharma ranks #503 out of 511 companies in the Drug Manufacturers industry, placing it in the top 98.4%.
Is Piramal Pharma's Dividend Yield % too high?
Piramal Pharma's current Dividend Yield % of 0.07% is 17% above median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.10. The Drug Manufacturers industry median Dividend Yield % is 1.94. Piramal Pharma's value of 0.07% is 96.4% below this industry median. Based on the distribution chart, Piramal Pharma ranks #503 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Piramal Pharma has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Piramal Pharma ranks #503 out of 511 companies for Dividend Yield %. This places Piramal Pharma in the lower half of its industry. The industry median Dividend Yield % is 1.94. Piramal Pharma's value of 0.07% is 96.4% below this benchmark. Historically, Piramal Pharma's own Dividend Yield % has ranged from 0.04 to 0.10 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 1.94, Piramal Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.94, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Piramal Pharma's current Dividend Yield % of 0.07% is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Piramal Pharma and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Piramal Pharma's current Dividend Yield % is 0.07%, which is 17% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹190.03, compared to a current price of ₹210.24 — trading 10.6% above its estimated fair value. The current Dividend Yield % is 0.07%, which is 17% above median its 10-year median of 0.06 and 96.4% below the Drug Manufacturers industry median of 1.94. Piramal Pharma's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Dividend Yield % is 0.07% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?
Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued.
The current stock price of ₹210.24 is trading 10.6% above its estimated GF Value™ of ₹190.03.
GuruFocus considers Piramal Pharma to be Modestly Overvalued.
Key valuation signals for NSE:PPLPHARMA:
Dividend Yield %: 0.07% (17% above median its 10-year median of 0.06)
GF Value™: ₹190.03 vs. price of ₹210.24 (10.6% above fair value)
Industry Position: 96.4% below the Drug Manufacturers median (#503 of 511)
No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
50GF Score
Get the complete analysis for NSE:PPLPHARMA
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PPLPHARMA has been successfully added to your 
